key: cord-0029787-673rkx4f authors: Kapoor, Karan; Thangapandian, Sundar; Tajkhorshid, Emad title: Extended-ensemble docking to probe dynamic variation of ligand binding sites during large-scale structural changes of proteins date: 2022-03-16 journal: nan DOI: 10.1039/d2sc00841f sha: 8a4d087b5d24fc9ef82142685200a46bf298ed03 doc_id: 29787 cord_uid: 673rkx4f Proteins can sample a broad landscape as they undergo conformational transition between different functional states. At the same time, as key players in almost all cellular processes, proteins are important drug targets. Considering the different conformational states of a protein is therefore central for a successful drug-design strategy. Here we introduce a novel docking protocol, termed extended-ensemble docking, pertaining to proteins that undergo large-scale (global) conformational changes during their function. In its application to multidrug ABC-transporter P-glycoprotein (Pgp), extensive non-equilibrium molecular dynamics simulations employing system-specific collective variables are first used to describe the transition cycle of the transporter. An extended set of conformations (extended ensemble) representing the full transition cycle between the inward- and the outward-facing states is then used to seed high-throughput docking calculations of known substrates, non-substrates, and modulators of the transporter. Large differences are predicted in the binding affinities to different conformations, with compounds showing stronger binding affinities to intermediate conformations compared to the starting crystal structure. Hierarchical clustering of the binding modes shows all ligands preferably bind to the large central cavity of the protein, formed at the apex of the transmembrane domain (TMD), whereas only small binding populations are observed in the previously described R and H sites present within the individual TMD leaflets. Based on the results, the central cavity is further divided into two major subsites, first preferably binding smaller substrates and high-affinity inhibitors, whereas the second one shows preference for larger substrates and low-affinity modulators. These central subsites along with the low-affinity interaction sites present within the individual TMD leaflets may respectively correspond to the proposed high- and low-affinity binding sites in Pgp. We propose further an optimization strategy for developing more potent inhibitors of Pgp, based on increasing its specificity to the extended ensemble of the protein, instead of using a single protein structure, as well as its selectivity for the high-affinity binding site. In contrast to earlier in silico studies using single static structures of Pgp, our results show better agreement with experimental studies, pointing to the importance of incorporating the global conformational flexibility of proteins in future drug-discovery endeavors. Modern drug discovery is centered around the identication of suitable protein targets that play important roles in a specic disease, and the development of small molecules designed to either attenuate or promote the function of those targets. 1 Structural determination techniques such as X-ray crystallography and cryo-EM have led to a large number of structurally known proteins that can help guide the drugdiscovery process. 2, 3 Experimentally resolved structures, however, generally represent starting or end states in the functional cycle of a protein, as the conformational intermediates (usually shorter-lived) arising during the function are oen inaccessible under the experimental conditions. 4 This reduces the possible structural diversity of the target that can be utilized in designing more efficient drug-discovery strategies. Generating and targeting these conformational intermediates still remains a major challenge in successful drug-discovery campaigns. Computational methods are increasingly used to complement experimental drug-discovery strategies. 5, 6 Structure-based drug-discovery methods like docking utilize the available three-dimensional structure(s) of the target protein to make predictions for the best binding ligand candidates. 7, 8 The approach can signicantly reduce the number of chemotypes to experimentally synthesize and test, compared to a high-throughput screening approach utilized alone without prior knowledge of the potential interactions between the target and small molecules. 9 Traditionally, and given the structural determination challenges described above, only a single experimental (e.g., crystal or cryo-EM) structure or a single computational model (e.g., a homology model) of the target protein has been used for docking purposes, in an approach we refer to as single-point docking 10 (Fig. 1 ). As stated above, these structures generally represent only a static snapshot of one conformational state of the target protein. More recently, the single-point docking approach has been improved to take into account thermal uctuations of the target protein in an approach referred to as ensemble docking, which has been shown to enhance both the quality and the efficiency of lead prediction 11 and successfully applied to a number of protein targets [12] [13] [14] [15] (Fig. 1 ). Ensemble docking makes use of molecular dynamics (MD) simulations for sampling the conformational basin of the protein target in the vicinity of a starting structure. [16] [17] [18] [19] In order to improve the sampling of the local conformational basin, some studies have combined equilibrium MD simulations with enhanced sampling techniques, e.g., metadynamics, to broaden the range of protein conformations that can be then used in the following docking step. 20 In the case of larger and more exible protein targets though, which oen display a complex conformational landscape with multiple local minima, 4, 21, 22 the limited timescales of equilibrium MD simulations, even when combined with enhanced sampling techniques, may not cover the large conformational heterogeneity of the target protein. 23 Large-scale motions and state transitions are of high relevance to the function of many macromolecular systems, e.g., the transmembrane transport of substrates by membrane transporters, activation of receptors, and gating of channels. 4, 24, 25 Non-equilibrium methods allow us to expand our sampling of the phase space and to visit intermediate conformations formed during the transition between major functional states of a protein. 26, 27 This forms the basis of what we term here as the extended-ensemble docking, which uses enhanced sampling offered by non-equilibrium MD for generating an extended ensemble of the protein (in comparison to the more 'limited' ensemble of the protein usually generated in ensemble docking), sampling the full conformational transition pathway between functional end states (Fig. 1) . The extended ensemble of the protein can then be used to seed highthroughput docking calculations for specic drug-discovery applications. Here we report the rst application of this approach to the investigation of ligand binding in the ABC exporter, Pglycoprotein (Pgp), 28 a transporter that is over-expressed in the plasma membrane of cancer cells and is a major cause for the development of multi-drug resistance. 29, 30 Pgp accomplishes its function as a cellular 'vacuum cleaner' by binding of different classes of molecules 31, 32 to its large central drug binding pocket (DBP), formed between two opposing, pseudosymmetric transmembrane domains (TMDs) (Fig. S1 †) . As an active transporter, Pgp follows the general 'alternating-access' model, 33, 34 thus transitioning between inward-facing (IF) and outward-facing (OF) states, alternatively exposing the DBP (and any bound substrate) to the cytoplasmic and extracellular sides of the membrane. The large-scale structural transitions of the transporter are fueled by and coupled to ATP-driven dimerization and opening/closing motions of its two nucleotide binding domains (NBDs) connected to the TMDs 35-37 (Fig. S1 †) . A number of computational studies employing molecular docking, 38-40 pharmacophore mapping, 41 machine learning, 42 and MD-based approaches 43 have characterized the promiscuity of the ligand-binding sites in Pgp. However, these studies have generated vastly conicting results to each other and to earlier mutational studies; [44] [45] [46] it still remains debatable as to whether diverse molecules bind to distinct or overlapping binding sites in Pgp. A major limitation of in silico approaches to ligand binding is that they oen neglect structural heterogeneity inherent to a exible, multidomain protein such as Pgp by targeting only a single crystal structure/homology model, providing only a snapshot and ignoring the myriad of conformations arising during the function of a protein. In the present study, we use non-equilibrium, driven MD simulations employing system-specic reaction coordinates describing the alternate-access transitions of ABC transporters, in order to sample the full transition cycle of Pgp between the IF and OF states. Docking of diverse small molecules, including substrates, non-substrates, and modulators, to the generated extended ensemble of the protein reveals that different classes of compounds may bind distinctly to different conformational states/intermediates of Pgp. The captured differential ligandbinding properties of different "subsites" in Pgp, whose accessibility and size are modulated by the protein conformational changes as it undergoes transition between the IF and OF states Single-point docking utilizes a single structure of the protein target, restricting the sampling to a single point (orange dots) in the conformational landscape. Ensemble docking utilizes an ensemble of protein structures, often generated using MD simulations, taking into account thermal fluctuations within a local conformational basin in the vicinity of the starting experimental structure (blue lines). Extended-ensemble docking, the method introduced here, aims at taking into account the full functional cycle of the protein, generated, e.g., through the application of biasing techniques to transition between the major functional states of the protein (green lines). may be a determining factor in the broad substrate specicity of the transporter. Our results show a close relationship with previous experimental studies and additionally allow us to make suggestions for developing more potent inhibitors of this multidrug resistance transporter. The main distinction of extended-ensemble docking from other docking approaches is to rst generate structural models for the intermediate conformational states of the protein that arise during the transition between its structurally known states, e.g., through the application of biased simulation techniques. Then, instead of targeting a single experimental/modeled structure, the entire extended ensemble of the protein's conformations is targeted by high-throughput docking calculations (extendedensemble docking). Following are the details of the different steps involved in the protocol used to generate the target conformational ensemble and its specic application to Pgp (Fig. 2) . We also present a suitable method for clustering the predicted binding modes of compounds to the ensemble of structures, in order to obtain relevant results that are related to the mechanism of the protein. 2.1 General strategy to generate an extended conformational ensemble for the target protein We start with the available (known/modeled) structures of major functional states (end states) of the protein. In order to obtain relaxed structures, which are required for optimal The approach involves the targeting of an extended ensemble of the protein conformations, generated along its functional cycle, by docking small molecules, followed by clustering of the predicted binding poses for each representative conformation. See Methods for details of each step. sampling of the transition pathway between them, one would need to rst equilibrate them in a native environment, e.g., solution for globular proteins or a lipid bilayer for membrane proteins. Subsequently, in order to describe conformational transition between major states, we dene a set of system-specic collective variables (CVs) that capture the essential conformational changes in the protein during the transition. These CVs need to be closely related to important/relevant structural features of the different states; by applying time-dependent biases along these CVs, for example by using biased methods such as steered MD (SMD), 47 we can generate transition pathways connecting the end states. 22, 48 The amount of non-equilibrium work needed to induce the conformational change during a driven transition along a particular pathway (obtained from multiple simulation replicates) provides an approximate initial metric for the likelihood and relevance of the sampled transition pathway. 49, 50 At the same time, the RMSD of the resulting structure from the target structure provides a measure for the effectiveness of the prescribed protocol to complete the transition. Low RMSD to the target and low non-equilibrium work values for a pathway/ mechanism point towards the efficiency and quality of the applied transition protocol. An extended conformational ensemble of the protein can then be generated by selecting structures spanning the distance (along the CV space) between the two end states, for example, by uniformly selecting representative conformations along the optimal transition pathway. In the following sections we describe each of these steps for the specic example of Pgp. 2.1.1 Equilibration of functional states of Pgp. In the case of Pgp, crystallographic studies have captured only the IF state of the transporter thus far. 31, [51] [52] [53] [54] Additionally, these crystal structures show different degrees of NBD separation, pointing to the conformational heterogeneity of the transporter in the IF state. Conventional MD simulations were thus employed rst to allow further sampling of the (local) conformational space of the IF state. We had previously generated an equilibrated ensemble of Pgp IF structures, 55 using independent MD simulations of the crystal structure of mouse Pgp (PDB: 4M1M 31 ) fully embedded in a POPC/cholesterol lipid bilayer. As binding of ATP/Mg 2+ to the NBDs of the transporter is a prerequisite for their dimerization and progression of the catalytic cycle, ATP/ Mg 2+ were carefully modeled into their respective binding sites in the NBDs following the protocol described by Wen et al., 56 that reproduces the conserved nucleotide-binding characteristics observed in high-resolution ABC transporter structures. As for the OF state, recently a cryo-EM structure of Pgp in this state was published. 57 Due to a Q/E mutation at the catalytic site of the structure, it has been suggested to be a 'dead mutant', a non-catalytic form of Pgp incapable of substrate transport. 58 Other structural studies have instead suggested this structure to represent a post-transport, collapsed/occluded state of the transporter. 59 Additionally, studies using DEER spectroscopy have shown that Pgp samples a wider opening (not seen in the cryo-EM structure) on the extracellular side of the TMDs in its OF state during the catalytic cycle. 60 Due to these reasons, we have generated our own equilibrated model of the Pgp OF state using careful sequence alignment, homology modeling, and SMD simulations, and tested its stability in multiple MD simulations. 60 The distances between different regions of the transporter in this state were found to match well with the DEER spectroscopy results. 60 2.1.2 System-specic CVs for sampling conformational transition. In our previous work with ABC transporters, including Pgp, we developed a set of specic CVs to capture the motion associated with the alternate-access mechanism of these transporters. 50, 60 Conformational transition between the equilibrated IF and OF states of Pgp was carried out using these system-specic CVs, controlling both the global conformational changes of the protein during the transition, as well as local interactions (e.g., domain-domain interfacial interactions) crucial for the formation of stable Pgp states (Fig. S2 †) . These included two orientation-based CVs (quaternions), denoted as a and b, describing the closing/opening of the TMDs on the cytoplasmic and extracellular sides, respectively. These specic orientation quaternions are dened on the basis of the Ca positions of the two TMD bundles in IF and OF structures, respectively, and are associated with the relative rotation of the helices during the transition between the IF and OF states (see Verhalen et al. 60 for more details). Additionally, one CV, denoted as SB, controls the formation of a salt-bridge interaction (K185-D993) in the middle of the TM helical region that may stabilize the cytoplasmic closure of the TMD in the OF state. Furthermore, for appropriate dimerization of the NBDs during the formation of the OF state, 12 CVs (collectively denoted as NBDi) were used to enforce distances between different atoms of ATP in each NBD and the signature motif (LSGGQ) of the opposing NBD, and between NBDs X-loops and coupling helices located at the interface between the TMD and NBDs (Table S1 †). All the target distances for NBDi CVs were obtained from the highresolution crystal structure of the dimerized NBDs in HlyB (PDB: 1XEF 61 ), an ABC exporter. 2.1.3 Driving structural transition using SMD simulations. We then performed SMD simulations employing different driving protocols, each dened by applying a distinct order of the four system-specic CVs described above (a, b, SB and NBDi), to explore a wide range of mechanistically distinct transition pathways in Pgp. The transition protocols included: P1: a + NBDi + SB / b, P2: NBDi / a + SB / b, P3: a + SB / NBDi / b, and P4: a + NBDi + SB + b, where '+' indicates that the CVs were applied simultaneously, and '/' denotes their sequential application. SMD simulations were performed starting from 20 equilibrated ATP/Mg 2+ -bound IF structures of Pgp that were already embedded in POPC/cholesterol lipid bilayers, solvated and neutralized with Na + and Cl À ions, 55 and targeting the equilibrated model of the OF state, 60 using the 4 transition protocols (P1, P2, P3 and P4). This amounted to a total of 80 (20 starting structures  4 transition protocols) independent SMD runs. All simulations were performed using NAMD 62,63 with the CHARMM36 force eld representing protein, lipid, and nucleic acids [64] [65] [66] and the TIP3P model for water. 67 The simulations were carried out in an NPT ensemble, with the temperature maintained at 310 K using Langevin dynamics 68 with a damping coefficient of g ¼ 0.5 ps À1 , and the pressure maintained at 1 bar using the Nosé-Hoover Langevin piston method. 69, 70 Periodic boundary conditions were used, and long-range electrostatic forces were calculated using the particle mesh Ewald (PME) method. 71 The non-bonded interactions were calculated with switching and cutoff distances of 10Å and 12Å, respectively. A 2 fs integration timestep was used for calculating the forces. Eighty independent SMD runs were performed each for 30 ns to bring the starting structure close to the target orientations and distances (Table S1 †). Harmonic force constants of 10 5 kcal mol À1 rad À2 and 2 kcal mol À1ÅÀ2 were used for the quaternion-based and distance-based CVs, respectively. Subsequently, non-equilibrium work proles and Ca RMSD with respect to the target OF structure were calculated using in-house TCL scripts in VMD. 72 2.1.4 Using the lowest-work transition pathway to select an extended ensemble. In the next step, starting with an equilibrated IF structure with largest RMSD to the target OF structure we ran a longer (100 ns) SMD simulation using the most efficient transition protocol (lowest work value protocol from the set of shorter SMD runs described above). The trajectory of this run was used to generate the extended ensemble of conformations of the protein. These longer (slower) SMD simulations decrease the non-equilibrium work required for the structural change and allow the protein to remain closer to a low-energy path during the transition. An ensemble of the protein conformations was then extracted by taking 50 snapshots from the trajectory distributed nearly equally along the CV phase-space (equally spaced in time). We also analyzed the conformational modulation of the putative binding pockets in the Pgp ensemble over the course of the transition using Site Finder in Molecular Operating Environment (MOE), 73 that calculates both the size and the ligand-binding propensity (based on the aminoacid composition) of the predicted binding pockets (also termed active binding pockets). In extended-ensemble docking, we utilize the conformations and intermediate states generated along the global transition pathway of a protein for docking. The selection of a suitable docking methodology generally depends on the specic goal of the study. In the following section we describe the steps involved in the docking calculations carried out in the extended ensemble of Pgp. In order to compare the results obtained from our extendedensemble approach with other in silico studies, we used a previous docking study 39 conducted on the crystal structure of the IF state of Pgp (PDB: 4M1M 31 ) as a point of reference. From this study, we obtained a set of 14 compounds from different ligand classes for Pgp (substrates, non-substrates and high-and low-affinity modulators). These molecules have been shown to bind to overlapping sites within the TMD by mutational studies. 44, 45 Docking of compounds, while allowing exibility around all rotatable bonds, was carried out using Autodock Vina 74 in the extended ensemble of pgp along with the starting crystal structure of the IF state (Fig. 3 ). All structures were superimposed on the starting crystal structure, centered at (0, 0, 0), to discount for the translation and rotation of the protein during the simulation. A common docking grid box was then dened around the extended ensemble covering the TMD apex (putative binding sites) of the protein. This box centered at (0, 0, 40) had dimensions of 80, 54, and 80Å in the x, y and z directions, respectively (Fig. 3) . Docking of compounds was carried out in this grid box in an agnostic manner, i.e., the compounds were allowed to sample the entire binding space within the box without any constraints. A total of nine binding poses were generated for each docked compound in each protein conformation. In Autodock Vina, the docking calculation consists of a number of independent runs each consisting of several sequential steps (the number of steps in a run is determined heuristically, based on the size and exibility of the ligand). Each independent run is started with a ligand in random conformation, orientation and torsions inside the docking grid box. 75 Due to the larger size of the grid box used for the TMD of the protein, we have set the exhaustiveness parameter to a large value of 200. This translates to a total of 200 independent docking runs, each starting from a different random ligand conguration in the grid box, thus providing 25 times more sampling compared to the default sampling rate (default exhaustiveness value of 8), thereby decreasing the possibility of missing relevant poses. In order to check the reproducibility of the results at the selected sampling level, we have also repeated the docking runs 4 times for 4 representative compounds with the employed exhaustiveness value of 200; the results show close similarity indicating that at this exhaustiveness, one can expect a high level of reproducibility. Given the large structural diversity of conformations obtained from the extended ensemble, geometrical clustering of the predicted binding poses can be challenging. To overcome this problem, we rst dened a hybrid system of reference, which combines independent points in space with protein-dependent points to assign positions/distances to the bound ligand. The resulting distances were then used in clustering. This clustering strategy can be generalized to other similarly exible protein targets. For each protein conformation in the extended ensemble, 6 reference points were dened (Fig. S3 †) : four xed points at the centers of the four faces of the grid box along the y and z axes (Ày, +y, Àz, and +z; these points are the same for all protein conformations), and two protein-dependent points used to track the main structural change of the protein along the transition pathway, namely opening and closing of the cytoplasmic mouth (Àx, +x, corresponding to the cytoplasmic ends of two of the TMD helices). For the xed points, we used the docking grid box dened around the TMD region (centered at (0, 0, 40) with dimensions of 80, 54, and 80Å in the x, y and z directions, respectively); the four xed points lied at (0, 27, 40), (0, À27, 40), (0, 0, 0) and (0, 0, 80), respectively. The two variable points in AE x were the position of the Ca atoms of the rst residues of TM1 (L45) and TM7 (P705) helices, respectively. The six-dimensional distance vector between the center of mass of the docked compound and these reference points were used for the hierarchical clustering method in MATLAB. 76 In the rst step of clustering, a pairwise dissimilarity matrix was composed (based on the distances dened above) for all the docked poses. This symmetric dissimilarity matrix consisted of 6300 2 elements (6300 ¼ 50 protein conformations  14 compounds  9 binding poses/compound). In the second step, a hierarchical tree was constructed by linking proximal poses (based on the dissimilarity matrix) using the average linkage method. 77 In the third step, a distance cutoff was used for pruning the branches of the hierarchical tree, allowing partitioning of all points lying below a specic branch into individual clusters. A cutoff of 15Å resulted in a suitable partitioning of the hierarchical tree with different pruned branches representing the clusters, representing binding to different sites/regions of the protein. The binding of different compounds to the extended ensemble of the Pgp was characterized in terms of the predicted binding affinities for the different binding modes of each compound in each cluster, as well as the relative population distribution of these compounds in each cluster. The predicted binding affinities for each binding mode were obtained from the Autodock Vina output. Mapping of these clusters onto the TMD of Pgp allowed identication of the corresponding binding sites in the protein along with the residues with the highest overall contact frequencies. The protein residues interacting with the predicted binding modes were identied using in-house scripts in VMD; 72 any protein heavy atom within 4Å of a ligand heavy atom was considered to form a contact and to contribute to the binding site. Here, we describe the results of the extended-ensemble docking approach to the multi-drug transporter Pgp. The results pertinent to the generation of the extended ensemble using SMD simulations are provided in the ESI (Fig. S4-S8 †) . The reproducibility of the docking results was checked by repeating the docking runs and also provided as the ESI (Fig. S9 †) . Here, we rst describe the results evaluating possible binding sites formed in Pgp as it transitions from the IF to OF state. The results highlight differential binding modes and affinities to the different conformations of Pgp. Furthermore, the calculations allowed us to differentiate between the different classes of compounds based on their binding preference for specic sites in Pgp. Analysis of the characterized binding pockets allowed us to evaluate their response to the global changes of the protein. Three binding pockets are formed in the membrane encompassing region of the TMDs (Fig. 4) . Out of these, the pocket at the TMD apex (where the two TMD leaets meet; shown in blue in Fig. 4 ) displays a high ligand binding propensity in all conformations except in snapshot 50 representing the OF state of Pgp (Table S2 † ). The disappearance of this binding pocket in the OF state can be attributed to its signicant shape change in this state, due to the rearrangement of TMD helices (Fig. 4G) . The largest size for this pocket (along with the highest ligandbinding propensity) is observed in snapshot 30 (Fig. 4E) which is an IF-like state similar (RMSD of 3.2Å) to the starting crystal structure (Fig. 4A) . The other two binding pockets in the DBP lie within the individual TMD leaets (shown in red and green in Fig. 4) , and show relatively smaller sizes and lower ligand-binding propensities in different protein conformations compared to the apex binding pocket. Additional small binding pockets exhibiting low ligand-binding propensities are also observed to form in the late conformations in the Pgp extended ensemble, either on the cytoplasmic side, where the two TMD leaets come together and close the cytoplasmic entry to the protein lumen (shown in pink in Fig. 4F ) or on the extracellular side, where the two TMD leaets separate and lead to an extracellular opening (shown in yellow in Fig. 4F and G) . The tested compounds show different binding affinities to different protein conformations (Fig. 5 and S10 †) . Interestingly, all the compounds show stronger binding affinities (more negative docking scores) in conformations other than the starting IF crystal structure, in some cases reaching binding affinities as much as À4.1 kcal mol À1 better than the crystal structure (laniquidar shown in Fig. S10 †) . In general, highaffinity Pgp modulators (laniquidar, tariquidar and zosuquidar) show stronger binding affinities than low-affinity modulators (QZ59), large substrates (doxorubicin and vinblastine), and small substrates (hoechst, verapamil, progesterone, prazosin, rhodamine, and colchicine). Consistent with their known properties, non-substrate ligands (diphenhydramine, trimethoprim) show the weakest binding affinities among all the compounds. Overall for the majority of the compounds, we observe an increasing trend in predicted binding affinities (becoming stronger binders) for protein snapshots 30-40 ( Fig. 5 and S10 †). Pgp transitions from open IF to closed IF-like conformations in these snapshots. Correspondingly, the DBP changes from a 'atter' shape, in which part of the ligand may not form favorable interactions with the protein and instead remain solvent-exposed (on the cytoplasmic side), to a more compact shape, that may allow favorable interaction with TM helices in the DBP. Furthermore, the binding affinities become weaker for most of the compounds in protein conformations 40-50 ( Fig. 5 and S10 †). Pgp transforms from the IF into an OF-like conformation during this phase of the transition, exhibiting largescale rearrangements in the DBP, which becomes solvent exposed from the extracellular side, and as a result shows decreased binding affinities. The hierarchical clustering of binding modes obtained for the tested compounds allowed us to characterize their preference for different binding regions of Pgp. Using a cutoff distance of 15Å the resulting hierarchical tree was partitioned into 12 separate clusters (Fig. S11 †) . The relative populations of the clusters showed that clusters 4 and 5 together constituted majority ($78%) of all predicted binding modes. Mapping of the clusters onto the protein TMDs showed that clusters 1, 2 and 3 (named E1, E3 and E2 sites, respectively) are within the extracellular side of the TMDs, clusters 4, 5 and 11 (named M1, M2, and M3 sites, respectively) are within the apex of the TMDs, clusters 6 and 7 (named R2 and R1, respectively) represent binding to TMD2, Cluster 8 (named S1) represents binding to membrane-facing surface of TMD2, Cluster 9 (named S2) describes binding to the intracellular end of the TMDs, and clusters 10 and 12 (named H1 and H2, respectively) are related to binding to TMD1. The naming convention for binding sites assigned is further described in Discussion. High-affinity modulators (laniquidar, tariquidar and zosuquidar) and small substrates (hoechst, verapamil, progesterone, prazosin, rhodamine, and colchicine) show high populations at the M1 site at the apex of the DBP, whereas the low-affinity modulator (QZ59) and large substrates (doxorubicin, vinblastine) show preferential binding to M2, which is also located at the apex of DBP but closer to TMD2 (Fig. 6 , S12 † and Table 1 ). Overall, M1 and M2 binding sites show relatively stronger binding affinities for all tested compounds. The M3 site, below M1 and towards TMD1, is generally only sparsely populated, except for large substrates and low-affinity modulators, which show moderate populations at this site (Fig. 6 , S12 † and Table 1 ). This binding site (M3) only forms during the late transition to the OF state ( Fig. 7 and S13 †). R1 and R2 sites are below the M2 site in TMD2, whereas H1 and H2 sites are present below the M3 site in TMD1 ( Fig. 6 and S12 †). Low-affinity modulators and large substrates display moderate binding populations to R1/R2 sites, while small substrates like prazosin show moderate binding to H1 ( Table 1) . The H2 site, on the other hand, shows marginal binding populations for all compounds. In general, R1 and H1 are seen to form in protein conformations 1-30, while the protein is still in IF-like conformations, whereas R2 and H2 sites are sampled more during the later phase of the transition (conformations 30-50), with the protein in OF-like conformations ( Fig. 7 and S13 †). Extracellular sites E1 and E2 are found in OF-like conformations (conformations , where the DBP opens up towards the extracellular side ( Fig. 7 and S13 †). Most compounds bind with substantial populations to the E2 site, whereas E1 shows only marginal binding (Fig. 6 , S12 † and Table 1 ). Some of the compounds also show binding to an additional extracellular site, E3, on the extracellular surface of the TMDs. This site is found only during the early phase of the protein transition (snapshots 1-30), i.e., in IF-like states, and hence it may not represent a physiologically important site for the substrates as the DBP in these conformations is inaccessible from the extracellular side. Other than the above ten binding sites, some compounds show binding to two additional subsidiary sites S1 and S2, with S1 located on the membrane-facing surface of TMD2 between the elbow helix and the broken (unstructured) region of TM12 (Fig. 6 , S12 † and Table 1) , and S2 at the bottom of the TMDs between TM4 and TM6. S2 is found only in the late protein conformations (snapshots 40-50), i.e., in OF-like states, and, similar to E3, may not represent a physiologically important site as the DBP may become inaccessible in these conformation due to the closing of the TMDs on the intracellular side during the IF-OF transition. The contacts formed by the protein residues with each compound were further analyzed and quantied as interaction frequencies. Comparatively, high-affinity modulators (laniquidar, tariquidar and zosuquidar) and some substrates (progesterone and verapamil) show higher interaction frequencies with the same set of residues as the low-affinity modulator (QZ59) and both large (doxorubicin and vinblastine) and small substrates (colchicine, hoechst, prazosin, and rhodamine) ( Fig. 8 and S14 †) . The non-substrate trimethoprim shows the lowest interaction frequency among all compounds, relating to its low selectivity for Pgp. Overall, most compounds form highly favorable interactions with residues in TM1, TM5, TM6, TM7, TM11, and TM12, which come together to form the DBP, with the exception of large substrates and the low-affinity modulator that instead display higher interactions with TM4 residues. Based on the most frequently (top 10) interacting residues, all compounds display binding preference for a set of core aromatic/ hydrophobic residues present at the apex of the DBP: Y306, L335, I336, F339 and F979 ( Fig. 9 and Table 2 ). High-affinity modulators and small substrates additionally show binding preference for a set of majorly aromatic residues, also lying close to the apex of the DBP: M68, F71, F332, F728, Y949, F974 and M982. The lowaffinity modulator and large substrates, on the other hand, show preference for a different set of mostly hydrophobic residues of the DBP present in the TMD2: I221, I225, I295, I298, I299, M986 and M990. As high-affinity modulators/smaller substrates and low-affinity modulator/large substrates do not share any binding residues other than the core ones, these compounds likely bind to distinct but overlapping sites in Pgp. The predicted binding residues for the docked compounds were further compared with the available experimental studies for these compounds in Pgp, including binding and transport mutagenesis studies, cysteinescanning mutagenesis, photoaffinity labeling and X-ray crystallography and cryoEM structures. The data have been presented in Table 2 . Ranking of the compounds based on their predicted binding affinities to the highly populated M1 site shows that highaffinity modulators bind with the strongest affinities to the extended ensemble, whereas non-substrates display the weakest binding affinities (Fig. 10A) . The substrates and the low-affinity modulator lie between these two extremes. High-affinity modulators and most substrates also display high binding populations in the M1 site, ranging between 40 and 80% for the different compounds (Fig. 10B) . In contrast, the low-affinity modulator and large substrates show low binding populations in the M1 site, and instead display higher binding populations in the second major binding site of the protein, the M2 site (Table 1) . We have put forth a protocol (Fig. 2) , termed extended-ensemble docking, that can be used to characterize the binding of small molecules to proteins undergoing large-scale conformational changes during their function. Employing the technique to the case of the multidrug resistance protein, Pgp, here we make use of a specically designed SMD protocol utilizing system-specic CVs to describe the structural transitions of the protein and to generate an extended ensemble to be used in docking. Multiple runs with different CV protocols allowed us to identify a lowwork transition pathway, likely corresponding to the most mechanistically relevant transition pathway connecting the two major functional states of Pgp (IF and OF). An extended ensemble of the protein was then generated along this transition pathway followed by a series of docking and clustering calculations, aiming at further characterization of the different binding sites in Pgp as they evolve during the transport cycle of the transporter. The global conformational changes during the transport cycle of Pgp modulate the size and shape as well as the ligandbinding propensities of the binding pockets (Fig. 4) . Radioligand binding assays characterizing the binding of Pgp substrates as well as a study showing the conformational sensitivity of drug-binding affinity and reactivity to an antibody have shown that binding sites in Pgp can display differential affinities for substrates depending on the conformation of the transporter that might arise during its catalytic cycle. 78, 79 In the present study, these differences are reected in the large variations observed in the predicted ligand binding affinities to the protein's extended ensemble (Fig. 5) . All compounds display stronger binding affinities to conformations other than its crystal structure, suggesting that experimentally determined protein structures may not necessarily represent the best interaction between the transporter and its substrates. Previous drug-drug interaction studies utilizing uorescence spectroscopy, 80, 81 and kinetic measurements of substrate binding and transport 82,83 as well as competitive binding assays 84, 85 have postulated at least 3 binding sites within the TMDs of Pgp. These sites have been termed as H and R sites 80, 81 showing preference for substrates hoechst and rhodamine, respectively, and the modulatory M site showing preference for vinblastine 45, 84 and verapamil, 82,83 two compounds that have been described to function as both modulators and substrates of Pgp. [86] [87] [88] [89] A previous single-point docking study targeting the crystal structure of Pgp in the IF state assigned the above sites to different regions in the TMDs but showed that the docked compounds do not display binding preference for any specic site (i.e., the compounds showed similar binding affinities to all 3 sites). 39 Here, in contrast, we show that all compounds show binding preference for only one major substrate/modulator binding site, analogous to the M site, encompassing the apex of the DBP, whereas the sites in the lower half of the DBP and in individual TMD leaets, analogous to the H and R sites described above, show low binding populations and comparatively weaker binding affinities for all tested compounds. The H and R sites may thus only function as poly-specic interaction sites in Pgp. We also report an interaction site on the membrane-facing surface of the TMD2, named the S site, as well as additional sites formed on the extracellular side of TMDs which form as the transporter undergoes transition to the OF state (E sites) and may assist in the extrusion of molecules out of the transporter. Based on mapping of the clustering results onto the protein structure, the M site is found to consist of 3 subsites, which we term M1, M2 and M3. The M1 subsite is positioned in a central location at the apex of the TMDs, allowing interactions with Fig. S14 †) . The residues are considered to interact with the ligand if their heavy atoms are within 4Å. The orange arrows point to the regions of the protein showing differences in their interaction patterns for different classes of compounds. High-affinity modulators like zosuquidar display the highest interaction frequencies with the binding residues pointing to a more specific mode of their binding. Fig. 9 Ligand binding residues identified in Pgp. Binding residues in Pgp showing the highest (top 10) interaction frequencies (from Fig. 8 and S14 †) with the tested compounds are shown in color within a cartoon representation of the protein backbone (left) and in stick representation (inset, right). The TM helices are individually labeled in the inset. The binding residues common to all compounds are shown in blue, residues common to binding of small substrates/high-affinity modulators in red, residues common to low-affinity modulators/large substrates in yellow, those common to small substrates/low-affinity modulators in orange, and residues showing preference for only small substrates are shown in green. High-affinity modulators share all binding residues with small substrates and show binding preference for the M1 subsite, whereas low-affinity modulators and large substrates show binding preference for residues forming the M2 subsite, lying below the M1 subsite and partially overlapping with it. residues from multiple helices from both TMD leaets. The M1 subsite may represent the central binding site for substrate molecules (Fig. 6) . High-affinity modulators are also predicted to bind to M1 but with relatively stronger binding affinities and higher interaction frequencies than the substrates, pointing to a more selective binding mode for these compounds ( Fig. 7 and 8) . The top binding residues predicted for these compounds show excellent correlation with the recent cryo-EM structures of Pgp in the complex with these compounds 90 (Table 2) . These modulators, showing IC 50 values in the nanomolar range, [91] [92] [93] can also function as strong third-generation inhibitors of Pgp and may directly compete with binding of low-affinity substrates. Alternatively, as suggested by a recent MD study, the stable binding of a third-generation inhibitor (tariquidar in this case) inside the DBP may promote increased lipid diffusion inside the lumen, locking Pgp in a catalytically inactive open IFlike state. 94 This may further enhance the inhibitory function of these molecules. Substrates verapamil and progesterone bind to the M1 subsite with high interaction frequencies comparable to highaffinity modulators, but with relatively weaker binding affinities. Binding residues predicted in our study, especially for verapamil, have been shown to be important for binding in several mutagenesis studies [95] [96] [97] [98] [99] [100] [101] (Table 2) . These molecules show IC 50 values in the micromolar range and were previously characterized as rst-generation inhibitors of Pgp. 102 They require high concentrations to fully inhibit the transporter, to the degree that they start to display toxicity and thus not suitable for administration. 103 A recently published cryo-EM structure shows binding of a substrate molecule taxol to the M1 subsite, 104 whereas another structure shows two zosuquidar molecules bound to the M site of Pgp, with the rst molecule occupying the M1 subsite and the second one occupying the M2/M3 subsites. 59 These structural studies provide further evidence that the M1 subsite described in our study may represent the central substrate/modulator binding site in Pgp. Combining the predicted binding affinities of all compounds in the different binding sites obtained in the extended ensemble ( Fig. 7 and S13 †), we observe differences in the relative binding affinities of the poly-specific interaction sites (H/R/S), modulation sites (M1/M2) and extracellular sites (E). These differences may facilitate the transport of the molecules from the inside to the outside of the cell. Larger low-affinity modulator QZ59 shows preference for the M2 subsite, with some binding in the M1 and M3 subsites. The crystal structure of Pgp with this modulator shows two copies of the ligand bound, with the rst copy located in a site similar to the M2 subsite described in our study (partially within the TMD2 leaet of Pgp), and the second copy located in the M1 subsite. 31 As expected, the top binding residues predicted in our study show good correlation with the above crystal structure binding site (Table 2 ). In multiple crystal structures of Pgp in the complex with structural analogs of QZ59, simultaneous binding of two ligands has also been observed to the M2/M1 or M3/M1 subsites. 53 Larger substrates like doxorubicin and vinblastine also show a similar binding behavior to the low-affinity modulator studied here, with a preferential binding for the M2 subsite, though some binding was also observed for the M1 and M3 subsites. The binding residues predicted for these molecules are further supported by several mutagenesis and photoaffinity experiments 95, 97, 101, [105] [106] [107] (Table 2 ). Similar to the QZ59 analogs, it is possible that two (or more) substrates more stably bind together to the multiple M subsites. Mapping of the clustering results on the protein structure further showed that the H and R sites identied in the separate TMD leaets (showing much lower binding populations compared to the M site), each consisted of two subsites, H1 and H2, and R1 and R2, respectively (Fig. 6) . The H1 and R1 subsites are found in open IF-like conformations and may be involved in initial interactions with the molecules as they partition from the membrane through the two proposed drug-entry portals located on either sides of Pgp. 51 An increase in the local concentration of molecules at these interaction sites may facilitate their binding to the central binding site (M1). The subsidiary S site (consisting of the S1 subsite) on the membrane-facing side of TMD2 may similarly facilitate formation of encounter complexes of substrates with the transporter, and it may function as an entry site for these molecules into Pgp. A similar interaction site has also been reported in the crystal structure of Pgp in complex with QZ-Valine, 53 a derivative of QZ59, in MD simulations of Pgp in cholesterol-rich lipid bilayers, 108 as well as in site-specic spin labeling studies of MsbA (a bacterial homolog of Pgp). 109 The extracellular E site, consisting of E1 and E2 subsites, represents novel binding sites identied in our study that partially overlap with the M1 subsite in the DBP and are formed as the TMDs open to the extracellular side during the formation of the OF state. These sites may play a role in assisting the diffusion of the substrate out of the transporter, as the DBP becomes exposed to the extracellular environment in the OF state. Experiments using photoaffinity labeling of Pgp substrates as well as crystal structures have suggested the presence of highand low-affinity binding sites in Pgp. 53, 110, 111 Potential of mean force calculations using umbrella sampling also identied multiple overlapping binding locations for different substrates in Pgp. 112, 113 The results of our extended-ensemble docking provide further support for this proposal, where the M1 and M2 subsites serve as the main binding sites for the high-affinity modulators/small substrates and large, low-affinity modulators/substrates, respectively (Fig. 11A) . These subsites form overlapping sites within the DBP of Pgp, with all modulators and substrates showing preference for the same set of core residues (Fig. 9) . The low-affinity binding sites proposed in the above studies may consist of the H, R and S sites located below the M site in the individual TMDs of Pgp. Correspondingly, the predicted binding affinities display an increasing trend between these low-and high-affinity binding sites (Fig. 11B) , likely promoting the diffusion of molecules towards the central binding site (M1) and their eventual extrusion through the extracellular sites. The differential binding behavior of the compounds to the above subsites in the extended ensemble of the protein further allowed us to differentiate between different classes of compounds (Fig. 10) . The availability of different binding sites, modulated by the conformational changes in the transporter, as well as modulation of their binding propensities may form the basis of poly-specicity of Pgp. Furthermore, information on molecules showing stronger binding affinity (specicity) to the protein extended ensemble instead of a single structure may provide a more complete framework for the development of specic, fourth-generation inhibitors of Pgp. Large exible proteins like Pgp have proven to be challenging drug targets, as a number of recent ventures in developing new drug molecules targeting it have failed. Further optimization strategies using crystal or cryo-EM structures can be technically difficult, as these proteins uctuate between different conformational states, concurrently leading to changes in the available/characterized binding sites. This challenge also represents a major roadblock for developing accurate structural-activity relationship models for conformationally heterogeneous proteins. Future endeavours in structure-based drug discovery targeting these proteins mandates new in silico strategies, taking into account the inherent exibility and crosstalk between the different domains of the protein as it undergoes transitions between major functional states. We have described here a new docking protocol pertaining to these systems, allowing high-throughput virtual screening of an extended ensemble derived along the protein's transition pathway, instead of targeting a single crystal/cryo-EM structure. This has allowed us to provide novel insights into the differential binding behaviors of different classes of compounds in Pgp. Future applications to other exible protein systems may open a new frontier in in silico drug design targeting these important drug targets. In addition to the use of SMD simulations applied in the present study, use of other enhanced sampling methods, for example, accelerated MD, has been suggested for improving the sampling of the protein phase space that can then be used for structure-based drug discovery. 114 Furthermore, free energy calculations incorporating Boltzmann reweighting of the conformations obtained from the biasing technique will provide additional enhancements to the approach outlined in this study. Post-processing the docking results based on the free energies of the different conformations constituting the extended-ensemble of the protein should take this approach even closer to the measured ligand binding properties of the protein. The full data set used in docking, including the extendedensemble of Pgp and the ligands used, is made available in Open Science Framework (OSF), https://osf.io/v7y8e/? view_only¼0f00e9fe832b4a1ea35e40e399e28c. KK and ET designed the research. KK and ST carried out all simulations. KK analyzed the data and wrote the manuscript dra. KK and ET edited and revised the manuscript. The authors declare no conict of interests. Target identication and mechanism of action in chemical biology and drug discovery New developments in crystallography: exploring its technology, methods and scope in the molecular biosciences The development of cryo-EM into a mainstream structural biology technique Protein ensembles: how does nature harness thermodynamic uctuations for life? The diverse functional roles of conformational ensembles in the cell Computational drug discovery A perspective on multi-target drug discovery and design for complex diseases The process of structure-based drug design A structure-based drug discovery paradigm Integration of combinatorial chemistry and structure-based drug design Structure-based drug design: aiming for a perfect t Multi-Conformer Ensemble Docking to Difficult Protein Targets Ensemble-Based Virtual Screening Reveals Potential Novel Antiviral Compounds for Avian Inuenza Neuraminidase Discovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei Discovery of novel nonactive site inhibitors of the prothrombinase enzyme complex Computationally identied novel agonists for GPRC6A An improved relaxed complex scheme for receptor exibility in computer-aided drug design Ensemble-based docking: From hit discovery to metabolism and toxicity predictions Ensemble Docking in Drug Discovery Supercomputer-based ensemble docking drug discovery pipeline with application to COVID-19 Holo-like and druggable protein conformations from enhanced sampling of binding pocket volume and shape Dynamic personalities of proteins Mechanistic picture for conformational transition of a membrane transporter at atomic resolution Equilibrium sampling in biomolecular simulations Glutamate transporters have a chloride channel with two hydrophobic gates Enhanced Sampling Techniques in Molecular Dynamics Simulations of Biological Systems Computational recipe for efficient description of large-scale conformational changes in biomolecular systems ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans The P-glycoprotein multidrug transporter The P-glycoprotein multidrug transporter Rened structures of mouse P-glycoprotein Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function A general theory of membrane transport from studies of bacteria Simple allosteric model for membrane pumps Structural insights into ABC transporter mechanism Structure and mechanism of ATP-binding cassette transporters Conformational changes in the nucleotide-binding domains of P-glycoprotein induced by ATP hydrolysis Keser} u, Homology modeling and binding site assessment of the human P-glycoprotein Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein Multiple transport-active binding sites are available for a single substrate on human P-glycoprotein (ABCB1) Cholesterol and cancer, in the balance Ligand and structure-based classication models for prediction of Pglycoprotein inhibitors Drug promiscuity of P-glycoprotein and its mechanism of interaction with paclitaxel and doxorubicin Biochemical, cellular, and pharmacological aspects of the multidrug transporter Identication and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators Processing Mutations Disrupt Interactions between the Nucleotide Binding and Transmembrane Domains of P-glycoprotein and the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Steered Molecular Dynamics Investigations of Protein Function Atomic-level characterization of transport cycle thermodynamics in the glycerol-3-phosphate:phosphate transporter Calculating relative transition rates with driven nonequilibrium simulations Mechanistic picture for conformational transition of a membrane transporter at atomic resolution Structure of P-Glycoprotein reveals a molecular basis for poly-specic drug binding Structures of P-glycoprotein reveal its conformational exibility and an epitope on the nucleotide-binding domain Snapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein Structures of the multidrug transporter P-glycoprotein reveal asymmetric ATP binding and the mechanism of polyspecicity Probing cholesterol binding and translocation in P-glycoprotein On the Origin of Large Flexibility of Pglycoprotein in the Inward-facing State Molecular structure of human Pglycoprotein in the ATP-bound, outward-facing conformation Mechanism of allosteric modulation of P-glycoprotein by transport substrates and inhibitors Structural insight into substrate and inhibitor discrimination by human P-glycoprotein H662 is the linchpin of ATP hydrolysis in the nucleotide-binding domain of the ABC transporter HlyB Scalable molecular dynamics with NAMD Scalable molecular dynamics on CPU and GPU architectures with NAMD Optimization of the additive CHARMM all-atom protein force eld targeting improved sampling of the backbone f, j and side-chain c 1 and c 2 dihedral angles Update of the CHARMM all-atom additive force eld for lipids: validation on six lipid types All-atom empirical force eld for nucleic acids: I. Parameter optimization based on small molecule and condensed phase macromolecular target data Comparison of Simple Potential Functions for Simulating Liquid Water Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-Alkanes Constant pressure molecular dynamics algorithms Constant pressure molecular dynamics simulation: The Langevin piston method Particle mesh Ewald: an N$log(N) method for Ewald sums in large systems VMD -Visual Molecular Dynamics Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910 AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function Data mining and knowledge discovery handbook Conformation, Localization, and Integrin Binding of Talin Depend on Its Interaction with Phosphoinositides A single active catalytic site is sufficient to promote transport in P-glycoprotein Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specicities Transport of LDS-751 from the cytoplasmic leaet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers Simultaneous Binding of Two Different Drugs in the Binding Pocket of the Human Multidrug Resistance P-glycoprotein Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Tryptophan scanning of D1S6 and D4S6 C-termini in voltage-gated sodium channels Structure of C-phycocyanin from Spirulina platensis at 2.2Å resolution: a novel monoclinic crystal form for phycobiliproteins in phycobilisomes In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1 In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576 Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979 Disposition of docetaxel in the presence of Pglycoprotein inhibition by intravenous administration of R101933 Active participation of membrane lipids in inhibition of multidrug transporter P-glycoprotein Identication of residues in the drug-binding site of human P-glycoprotein using a thiolreactive substrate Dening the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTSverapamil Permanent activation of the human P-glycoprotein by covalent modication of a residue in the drug-binding site Substrateinduced conformational changes in the transmembrane segments of human P-glycoprotein: direct evidence for the substrate-induced t mechanism for drug binding Transmembrane segment 1 of human P-glycoprotein contributes to the drugbinding pocket Transmembrane segment 7 of human P-glycoprotein forms part of the drugbinding pocket Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein Does inhibition of P-glycoprotein lead to drug-drug interactions? Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1 Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specicity of human P-glycoprotein Functional Evidence That Transmembrane 12 and the Loop between Transmembrane 11 and 12 Form Part of the Drugbinding Domain in P-glycoprotein Encoded by MDR1 Suppressor mutations in the transmembrane segments of Pglycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites Probing Cholesterol Binding and Translocation in P-glycoprotein Mapping daunorubicinbinding sites in the ATP-binding cassette transporter MsbA using site-specic quenching by spin labels Evidence for two nonidentical druginteraction sites in the human P-glycoprotein The remarkable transport mechanism of P-glycoprotein: a multidrug transporter Identication of possible binding sites for morphine and nicardipine on the multidrug transporter P-glycoprotein using umbrella sampling techniques Probing the pharmacological binding sites of P-glycoprotein using umbrella sampling simulations Enhanced molecular dynamics sampling of drug target conformations Identication of residues in the drug translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin Location of the rhodaminebinding site in the human multidrug resistance Pglycoprotein Pore-exposed tyrosine residues of Pglycoprotein are important hydrogen-bonding partners for drugs The authors acknowledge support by the National Institutes of Health under award numbers P41-GM104601 and R01-GM123455 (to E. T.). We also acknowledge computing resources provided by Blue Waters at National Center for Supercomputing Applications (NCSA).